Advanced biologics technology platform for next-gen immunotherapies
Total raised: $151.5M
Investors 2
| Date | Name | Website |
| - | Vida Ventu... | vidaventur... |
| - | The Column... | thecolumng... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 13.01.2025 | Series C | $80M | - |
| 07.10.2020 | Series B | $71.5M | Nextech In... |
Mentions in press and media 5
| Date | Title | Description |
| 13.01.2025 | A2 Biotherapeutics: $80 Million (Series C) Raised For Advancing Clinical Development Of Precision Cell Therapies | A2 Biotherapeutics – a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies to target tumor cells and protect normal cells selectively – announced the closing of its $80 million Series C financing round, ... |
| 18.01.2022 | A2 Bio to Present at ASCO-GI 2022 on Use of Next Generation Sequencing (NGS) to Identify GI Cancer Patients for Future Tmod™ CAR T Therapy | NGS assay by Tempus is able to identify GI cancer patients with clonal Human Leukocyte Antigen Loss of Heterozygosity (HLA LOH) for future Tmod™ CAR T Therapy AGOURA HILLS, Calif.–(BUSINESS WIRE)–January 18, 2022– A2 Biotherapeutics, Inc. (... |
| - | A2 Biotherapeutics | “Home | A2 Bio Therapeutics” |
| - | A2 Biotherapeutics | “A2 is dedicated to advancing cancer treatment through pioneering cell therapy. Our T cells target solid tumors with precision, transforming the future of medicine.” |
| - | The Column Group Raises a $725 Million Fourth Fund | The Column Group (TCG), a biotech venture capital firm focused on building innovative drug discovery companies, announced the closing of The Column Group IV (TCG IV) and its related investment vehicles totaling $725 million. With TCG IV, th... |